Avadel Stock Analysis

AVDL -  USA Stock  

USD 5.57  0.18  3.13%

The big decline in price over the last few months for Avadel Pharmaceuticals could raise concerns from stakeholders as the firm it trading at a share price of 5.57 on 638,739 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Avadel Pharmaceuticals Plc or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.03. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Avadel Pharmaceuticals partners.
Please continue to Trending Equities.

Avadel Stock Analysis 

 
Refresh
The Avadel Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Avadel Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Avadel Stock analysis module also helps to analyze the Avadel Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Avadel Stock Analysis Notes

About 55.0% of the company shares are held by institutions such as insurance companies. The book value of Avadel Pharmaceuticals was presently reported as 1.69. The company recorded a loss per share of 1.13. Avadel Pharmaceuticals had not issued any dividends in recent years. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Avadel Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. For more info on Avadel Pharmaceuticals Plc please contact Michael Anderson at 353 1 485 1200 or go to https://www.avadel.com.

Avadel Pharmaceuticals Quarterly Cost of Revenue

0.0Share

Avadel Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Avadel Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Avadel Pharmaceuticals Plc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Avadel Pharmaceuticals generated a negative expected return over the last 90 days
Avadel Pharmaceuticals has high historical volatility and very poor performance
Avadel Pharmaceuticals Plc was previously known as Avadel Pharmaceuticals Plc and was traded on NASDAQ Exchange under the symbol FLML.
The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (66.31 M) with profit before overhead, payroll, taxes, and interest of 16.59 M.
Avadel Pharmaceuticals Plc currently holds about 181.09 M in cash with (73.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.09.
Avadel Pharmaceuticals has a strong financial position based on the latest SEC filings
Roughly 55.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.taiwannews.com.tw: Global Myasthenia Gravis Market Projected to Boost at 3,263.50Mn And Growing at A CAGR of 7.99 percent By 3031 - Taiwan News

Avadel Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Avadel Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avadel Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of March 2022
Next Earnings Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Avadel Largest EPS Surprises

Earnings surprises can significantly impact Avadel Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
1999-02-23
1998-12-31-0.1-0.12-0.0220 
2019-11-12
2019-09-30-0.27-0.240.0311 
1997-03-26
1996-12-31-0.18-0.150.0316 
View All Earnings Estimates

Avadel Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Avadel Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Avadel Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Avadel Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
21st of January 2022
Unclassified Corporate Event
View
12th of November 2021
Unclassified Corporate Event
View
8th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
19th of October 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
18th of October 2021
Regulation FD Disclosure
View
15th of October 2021
Financial Statements and Exhibits. Other Events
View
9th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
4th of August 2021
Submission of Matters to a Vote of Security Holders
View

Avadel Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 337.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Avadel Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Avadel Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Avadel Profitablity

Avadel Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Avadel Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Avadel Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Avadel Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Avadel Pharmaceuticals' profitability requires more research than a typical breakdown of Avadel Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets 0.0276  0.0298 
Return on Average Equity 0.06  0.06 
Return on Invested Capital 0.0299  0.0323 
Return on Sales 0.41  0.44 

Management Efficiency

The entity has return on total asset (ROA) of (16.21) % which means that it has lost $16.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (49.09) %, meaning that it created substantial loss on money invested by shareholders. Avadel Pharmaceuticals management efficiency ratios could be used to measure how well avadel pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is expected to hike to 0.0298 this year. Return on Average Equity is expected to hike to 0.06 this year. Avadel Pharmaceuticals Asset Turnover is relatively stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at 0.09. Return on Average Assets is expected to hike to 0.0298 this year, although Tangible Assets Book Value per Share will most likely fall to 5.54.
Last ReportedProjected for 2022
Book Value per Share 3.52  3.80 
Enterprise Value over EBIT 63.25  68.24 
Enterprise Value over EBITDA 52.12  56.23 
Price to Book Value 2.76  2.83 
Tangible Assets Book Value per Share 6.40  5.54 
Enterprise Value500.4 M466.6 M
Tangible Asset Value339 M365.8 M

Technical Drivers

As of the 26th of January, Avadel Pharmaceuticals shows the mean deviation of 2.56, and Risk Adjusted Performance of (0.12). Avadel Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Avadel Pharmaceuticals Plc, which can be compared to its rivals. Please confirm Avadel Pharmaceuticals information ratio, and the relationship between the downside deviation and value at risk to decide if Avadel Pharmaceuticals is priced correctly, providing market reflects its regular price of 5.57 per share. Given that Avadel Pharmaceuticals has jensen alpha of (0.41), we suggest you to validate Avadel Pharmaceuticals Plc's prevailing market performance to make sure the company can sustain itself at a future point.

Avadel Pharmaceuticals Price Movement Analysis

The output start index for this execution was one with a total number of output elements of sixty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Avadel Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Avadel Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Avadel Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avadel Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avadel Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avadel Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kim Richard J over a month ago via Macroaxis 
Acquisition by Kim Richard J of 137500 shares of Avadel Pharmaceuticals subject to Rule 16b-3
Kim Richard J over a month ago via Macroaxis 
Acquisition by Kim Richard J of 137500 shares of Avadel Pharmaceuticals subject to Rule 16b-3
Glass Geoffrey Michael over three months ago via Macroaxis 
Avadel Pharmaceuticals exotic insider transaction detected
Palczuk Linda over three months ago via Macroaxis 
Acquisition by Palczuk Linda of 42000 shares of Avadel Pharmaceuticals subject to Rule 16b-3
Phillandas Thompson over six months ago via Macroaxis 
Avadel Pharmaceuticals exotic insider transaction detected
Kim Richard J over six months ago via Macroaxis 
Acquisition by Kim Richard J of 350000 shares of Avadel Pharmaceuticals subject to Rule 16b-3
Glass Geoffrey Michael over a year ago via Macroaxis 
Avadel Pharmaceuticals exotic insider transaction detected
Gregory Divis over a year ago via Macroaxis 
Acquisition by Gregory Divis of 500000 shares of Avadel Pharmaceuticals subject to Rule 16b-3
Mchugh Thomas S over a year ago via Macroaxis 
Purchase by Mchugh Thomas S of 4000 shares of Avadel Pharmaceuticals
Ende Eric J over a year ago via Macroaxis 
Purchase by Ende Eric J of 17000 shares of Avadel Pharmaceuticals
Mccamish Mark Anthony over a year ago via Macroaxis 
Acquisition by Mccamish Mark Anthony of 50000 shares of Avadel Pharmaceuticals subject to Rule 16b-3
Glass Geoffrey Michael over a year ago via Macroaxis 
Purchase by Glass Geoffrey Michael of 4800 shares of Avadel Pharmaceuticals

Avadel Pharmaceuticals Technical and Predictive Indicators

Avadel Pharmaceuticals Forecast Models

Avadel Pharmaceuticals time-series forecasting models is one of many Avadel Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Avadel Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Avadel Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Avadel Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Avadel shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Avadel Pharmaceuticals. By using and applying Avadel Stock analysis, traders can create a robust methodology for identifying Avadel entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin 0.49  0.53 
Gross Margin 0.67  0.71 
Profit Margin 0.36  0.39 
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Avadel Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Avadel Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module
Please continue to Trending Equities. Note that the Avadel Pharmaceuticals information on this page should be used as a complementary analysis to other Avadel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Avadel Stock analysis

When running Avadel Pharmaceuticals price analysis, check to measure Avadel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avadel Pharmaceuticals is operating at the current time. Most of Avadel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Avadel Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Avadel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Avadel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Avadel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Avadel Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.